Cybin Moves Forward With Clinical Trial On Psilocybin Oral Film

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced on Tuesday it has received initial clearance to begin a Phase IIa clinical trial on psilocybin for patients suffering from major depressive disorders (MDD).

The head-to-head will test Cybin’s proprietary sublingual psilocybin formulation against a 25mg psilocybin capsule on 40 patients.

The trial has been approved by a review board at the University of the West Indies in Jamaica, where the will be undertaken. The …

Full story available on Benzinga.com

More Cybin Moves Forward With Clinical Trial On Psilocybin Oral Film